JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 31 No. 9 1470-1473
© 1990 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loréal, O.
Right arrow Articles by Herry, J.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loréal, O.
Right arrow Articles by Herry, J.-Y.

Scintigraphic Assessment of Indium-111-Labeled Granulocyte Splenic Pooling: A New Approach to Inflammatory Bowel Disease Activity

Olivier Loréal, Annick Moisan, Jean-François Bretagne, Joseph LeCloirec, Jean-Luc Raoul, Joseph Gastard and Jean-Yves Herry

Department of Hepato-Gastroenterology, CHU, Pontchaillou, Rennes, France and Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France

Correspondence: For reprints contact: Annick Moisan, PhD, Department of Nuclear Medicine, centre Eugène Marquis, CHU Pontchaillou, 35033 Rennes Cedex - France.

ABSTRACT

We have conducted a prospective study into the sensitivity and the specificity of the fall in splenic activity (FSA) as an index of activity in inflammatory bowel disease (IBD). FSA was measured on scintiscans obtained at 3 and 24 hr postinjection of indium-111-labeled granulocytes. One hundred and twenty-two scans were acquired in 96 patients who were divided into six groups: Gr. I = normal volunteers (n = 10); Gr. II = inflammatory rheumatism (n = 10); Gr. III = abscesses (n = 17); Gr. IV = ulcerative colitis (UC:n = 23); Gr. V = colonic Crohn's disease (CCD: n = 22); and Gr. VI = ileal Crohn's disease (ICD: n = 14). FSA for Groups I and II was constantly below 10%, but it was increased in the other four groups (abscesses: 39% ± 12%; UC: 35% ± 13.5%; CCD: 23.7% ± 14.7%; ICD: 21.5% ± 11.7%). There was a significant correlation between fecal excretion of 111In (FEI) and FSA in patients with IBD (UC: r = 0.71, p < 0.001; CCD: r = 0.74, p < 0.001; ICD: r = 0.43, p < 0.001). FSA was followed in 16 patients with IBD after medical treatment and there was a significant correlation between variations in FSA and in FEI (r = 0.879, p < 0.001). FSA is a very sensitive although nonspecific index of disease activity in IBD and may replace FEI in the assessment of IBD activity.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1990 by the Society of Nuclear Medicine.